IDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $520.00

IDEXX Laboratories (NASDAQ:IDXX) had its price objective upped by Barclays from $481.00 to $520.00 in a report published on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts also recently commented on IDXX. Bank of America upped their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday. Stifel Nicolaus cut their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Morgan Stanley decreased their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. JPMorgan Chase & Co. dropped their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Piper Sandler reissued a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $524.38.

IDEXX Laboratories Trading Down 1.7 %

IDEXX Laboratories stock opened at $460.56 on Tuesday. IDEXX Laboratories has a 52 week low of $398.50 and a 52 week high of $583.39. The stock has a 50-day moving average price of $426.81 and a 200 day moving average price of $453.62. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $37.72 billion, a price-to-earnings ratio of 44.41, a price-to-earnings-growth ratio of 3.64 and a beta of 1.37.

Insider Activity

In related news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.18% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

Large investors have recently bought and sold shares of the company. International Assets Investment Management LLC boosted its stake in shares of IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after acquiring an additional 527,460 shares during the last quarter. Flossbach Von Storch SE boosted its stake in IDEXX Laboratories by 5,439.3% during the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after purchasing an additional 464,791 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after buying an additional 316,048 shares in the last quarter. Seilern Investment Management Ltd purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $113,104,000. Finally, Vontobel Holding Ltd. raised its position in shares of IDEXX Laboratories by 3,325.0% in the third quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock valued at $111,229,000 after buying an additional 213,731 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.